Aimei Health Technology (NASDAQ:AFJK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aimei Health Technology (NASDAQ:AFJK – Free Report) to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut Aimei Health Technology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Get Aimei Health Technology alerts:

View Our Latest Research Report on AFJK

Aimei Health Technology Trading Up 0.7%

Shares of NASDAQ AFJK opened at $12.19 on Friday. The firm’s 50-day moving average price is $12.10 and its 200-day moving average price is $26.75. The stock has a market capitalization of $38.63 million, a price-to-earnings ratio of 203.12 and a beta of 0.85. Aimei Health Technology has a 12-month low of $6.75 and a 12-month high of $130.37.

Aimei Health Technology (NASDAQ:AFJK – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter.

Hedge Funds Weigh In On Aimei Health Technology

A hedge fund recently raised its position in Aimei Health Technology stock. Clear Street Group Inc. raised its position in Aimei Health Technology Co., Ltd. (NASDAQ:AFJK – Free Report) by 36.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,337 shares of the company’s stock after purchasing an additional 22,294 shares during the quarter. Clear Street Group Inc. owned 1.36% of Aimei Health Technology worth $5,334,000 as of its most recent SEC filing. 45.58% of the stock is currently owned by institutional investors.

Aimei Health Technology Company Profile

(Get Free Report)

Aimei Health Technology Co, Ltd. (NASDAQ: AFJK) is a special purpose acquisition company (SPAC). Rather than operating a traditional health-care business, the company was established to identify and complete a merger, acquisition, or similar business combination with an operating company.

The company’s stated focus is expected to include businesses in the health-care and health-technology sectors. Before completing a transaction, Aimei Health Technology does not have a broad portfolio of products or services and may have limited operating activity beyond pursuing a suitable target and managing its corporate structure.

Aimei Health Technology is incorporated in the Cayman Islands and trades in the United States.

Featured Articles

• Five stocks we like better than Aimei Health Technology
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
• Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
• AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
• Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for Aimei Health Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimei Health Technology and related companies with MarketBeat.com's FREE daily email newsletter.